Biologic selection guided by epigenetic markers in Crohn's disease
Part of Digestive system clinical trials.
This trial compares two different ways to choose your Crohn's treatment: one based on a special test of your cells (epigenetic markers) and the other based on standard care. It aims to see which approach works better for people with moderate to severe Crohn's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a confirmed diagnosis of Crohn's disease in the small intestine, colon, or both.
- Your Crohn's is currently moderate to severe (your doctor will confirm this).
- You have not been treated with vedolizumab or ustekinumab before, and you've had no more than one other biologic or JAK inhibitor.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This study tests whether combining a specific diet with biologic medicines can reduce active inflammation and symptoms of Crohn’s disease. It may help people who still have active disease in the bowel despite prior care.
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
This study looks at people with Crohn's disease that is hard to treat. It aims to understand the disease better and see how well current treatments work.
This study looks at proteins from your body and gut bacteria to understand Crohn's disease better. You may join if you are about to have your first colonoscopy for suspected Crohn's and have not had any treatment yet.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.